The clinical and epidemiological profiles of differentiated thyroid cancers (DTCs) have
changed in the last three decades. Today's DTCs are more likely to be small, localized …

Differentiated thyroid cancer (DTC) is typically an indolent disease with a very low disease-
specific mortality. Although most cases are cured with a combination of surgical resection …

The treatment paradigm for thyroid cancer has shifted from a one-size-fits-all approach to
more personalized protocols that range from active surveillance to total thyroidectomy …

Differentiated thyroid cancer (DTC) is the most frequent endocrine malignancy and
represents the most rapidly increasing cancer diagnosis worldwide. In the last 20 years, this …

Although differentiated thyroid cancer (DTC) is typically an indolent disease with a high rate
of cure, recurrence is common (15%–30% of patients), even in early-stage disease. These …

The demography of differentiated thyroid cancers (DTCs) has changed considerably since
the 1990s, when the vast majority of these tumors were clinically evident at the time of …

Abstract Thyroid cancer affects 1.3% of the population with increasing rates of incidence
over the last decade (approximately 2% per year). Although the overall prognosis is good in …

Despite modern multi-modality treatment, 10–30% of patients treated for differentiated
thyroid cancer (DTC) ultimately develop local recurrence or metastatic disease. These …

The long-term survival of patients with thyroid cancer and the possibility of tumour
recurrence up to 30–40 years after the achievement of a disease-free status illustrate the …

Background: The incidence of well-differentiated thyroid cancer (WDTC) in the United States
is increasing rapidly. Much of this increase is due to the detection by imaging of small …